Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 1999

View Archived Issues

Mitsui Pharmaceuticals expands overseas clinical programs

Biomatrix receives go-ahead to test product for preventing lumbar postsurgical adhesions

Hyseq gene shown to be selectively expressed in lung cancer

Connetics completes patient enrollment in scleroderma pivotal trial

Excellent results obtained for Synsorb Cd against CDAD

DJ Pharma to market Schering-Plough antibiotic in U.S.

CytRx announces Flocor phase III results

Bayer allies with MorphoSys to accelerate drug discovery

FK-463, Fujisawa's antifungal agent, in late-stage clinical trials in U.S.

Licensing opportunity from NIH: antisense therapy for Crohn's disease

Inhale receives U.S. patent protection for pulmonary insulin

SuperGen, Abbott reach distribution agreement for anticancer drugs

Pfizer decides future focus of SERM program

Shire-Roberts merger completed

FDA clears Taxotere for marketing in NSCLC

Injectable levocarnitine approved for use in dialysis in U.S.

Abgenix cleared to become sole owner of XenoMouse technology

SuperGen acquires equity interest in AVI BioPharma and negotiating rights to Avicine

Asthma symptoms improve significantly, steroid use decreases in patients on anti-IgE therapy

Sugen succeeds in designing a potent, orally active PK inhibitor with antitumor activity

Brain cocaine receptor ligands from RTI with favorable properties for pharmaceutical, imaging use

New agents for muscarinic cholinergic system dysfunction synthesized at Novo Nordisk

SB designs new series of cathepsin K inhibitors

Janssen group presents preparation, activity and use of new PDE4/TNF-alpha inhibitors

Japanese patent covers BioSante's novel vaccine adjuvant/drug delivery system

Novel triazole antifungal agents developed in China

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...